Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma
Modern Pathology · 2024-03 · 37 (3) · 100420
DOI: 10.1016/j.modpat.2023.100420 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Modern Pathology, 2024-03. Verfasst von Christopher A Febres-Aldana und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Mesothelioma, Mesothelioma, Malignant, Pleural Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Mesothelioma Applied Research Foundation, National Institutes of Health.
Abstract (Originalsprache)
9p21 deletions involving MTAP/CDKN2A genes are detected in diffuse pleural mesotheliomas (DPM) but are absent in benign mesothelial proliferations. Loss of MTAP expression by immunohistochemistry (IHC) is well accepted as a surrogate for 9p21 deletion to support a diagnosis of DPM. Accurate interpretation can be critical in the diagnosis of DPM, but variations in antibody performance may impact interpretation. The objectives of this study were to compare the performance of MTAP monoclonal antibodies (mAbs) EPR6893 and 1813 and to compare MTAP expression by IHC with 9p21 copy number status in DPM. Cytoplasmic expression of MTAP IHC with mAbs EPR6893 (ab126770; Abcam) and 1813 (NBP2-75730, Novus Biologicals) was evaluated in 56 DPM (47 epithelioid, 7 biphasic, and 2 sarcomatoid) profiled by targeted next-generation sequencing. 9p21 Copy number status was assessed by Fraction and Allele-Specific Copy Number Estimates from Tumor Sequencing (FACETS) analysis and also by CDKN2A fluorescence in situ hybridization in discrepant cases when material was available. MTAP mAb 1813 showed stronger immunoreactivity, more specific staining, and no equivocal interpretations compared to mAb EPR6893 which showed equivocal staining in 19 (34%) of cases due to weak or heterogenous immunoreactivity, lack of definitive internal positive control, and/or nonspecific background staining. MTAP expression with mAb 1813 showed near perfect agreement with 9p21 copy number by combined FACETS/fluorescence in situ hybridization calls (κ = 0.85; 95% CI, 0.71-0.99; P < .001). MTAP IHC with mAb 1813 was 96% sensitive, 86% specific, and 93% accurate for 9p21 homozygous deletion. The findings of this study suggest that interpretation of MTAP IHC is improved with mAb 1813 because mAb EPR6893 was often limited by equivocal interpretations. We show that MTAP IHC and molecular assays are complementary in detecting 9p21 homozygous deletion. MTAP IHC may be particularly useful for low tumor purity samples and in low-resource settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
- Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: sauterj@mskcc.org.
Förderung
- NCI NIH HHS
- Mesothelioma Applied Research Foundation
- National Institutes of Health
- U.S. Department of Defense
- National Cancer Institute
Zitieren
APA
Febres-Aldana, C. A., Chang, J. C., Jungbluth, A. A., Adusumilli, P. S., Bodd, F. M., Frosina, D., Geronimo, J. A., Hernandez, E., Irawan, H., Offin, M. D., Rekhtman, N., Travis, W. D., Vanderbilt, C., Zauderer, M. G., Zhang, Y., Ladanyi, M., Yang, S. R., & Sauter, J. L. (2024). Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma. Modern Pathology, 37(3), 100420. https://doi.org/10.1016/j.modpat.2023.100420
Vancouver
Febres-Aldana CA, Chang JC, Jungbluth AA, Adusumilli PS, Bodd FM, Frosina D, et al. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma. Modern Pathology. 2024;37(3):100420. doi:10.1016/j.modpat.2023.100420
BibTeX
@article{FebresAldana2024,
author = {Febres-Aldana, Christopher A and Chang, Jason C and Jungbluth, Achim A and Adusumilli, Prasad S and Bodd, Francis M and Frosina, Denise and Geronimo, Jerica A and Hernandez, Enmily and Irawan, Helen and Offin, Michael D and Rekhtman, Natasha and Travis, William D and Vanderbilt, Chad and Zauderer, Marjorie G and Zhang, Yanming and Ladanyi, Marc and Yang, Soo-Ryum and Sauter, Jennifer L},
title = {Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma},
journal = {Modern Pathology},
year = {2024},
volume = {37},
number = {3},
pages = {100420},
doi = {10.1016/j.modpat.2023.100420}
}
EUVIMED